Katherine Wong, MD
Gastroenterology · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
Offices
2 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wong’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A148786 · Current
Licensed to practise in California · since 2017 · expires 2026-11-30 · Ross University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$83,314
Medicare paid this office $83,314 for 289 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 98 | $18,190 | $116 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 52 | $11,723 | $225 |
| New patient visit (45+ min) | 69 | $10,606 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $9,641 | $110 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 61 | $7,157 | $117 |
See all 8 services
| Return visit (30+ min) | 98 | $18,190 | $116 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 52 | $11,723 | $225 |
| New patient visit (45+ min) | 69 | $10,606 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $9,641 | $110 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 61 | $7,157 | $117 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 71 | $7,085 | $98 |
| Biopsy of large bowel using a flexible endoscope | 25 | $2,805 | $112 |
| Measurement of liver stiffness | 32 | $1,026 | $32 |
Procedures Medicare counted
| Colonoscopy | 72 | More than 72% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 102 | More than 77% of doctors who do this |
Who their Medicare patients are
289 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 17% · Women 61% · Also on Medicaid 10% · Health risk score 1.49. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Coronary heart disease 30% · Diabetes 29% · Chronic kidney disease 29% · Atrial fibrillation 25% · Depression 25% · Heart failure 24% · Cancer 19% · COPD 15% · Dementia 10% · Stroke 9%.
The office billed $557,803, Medicare allowed $107,123 and paid $83,314; for 649 services of 37 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 289 | 649 | 76 | 1.49 | $557,803 | $83,314 |
| 2023 | 390 | 3,192 | 76 | 1.27 | $581,605 | $134,906 |
| 2022 | 181 | 312 | 75 | 0.98 | $127,426 | $35,660 |
| 2019 | 80 | 227 | 80 | 3.04 | $79,175 | $19,527 |
| 2018 | 127 | 340 | 77 | 2.64 | $121,693 | $31,070 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Return visit (30+ min) | 135 | $18,941 | $108 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 83 | $18,311 | $221 |
| New patient visit (45+ min) | 75 | $10,013 | $134 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $9,703 | $105 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 76 | $6,684 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $6,303 | $154 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $2,875 | $115 |
| Diagnostic exam of large bowel using a flexible endoscope | 19 | $2,861 | $151 |
| Biopsy of large bowel using a flexible endoscope | 30 | $2,815 | $91 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | $2,482 | $99 |
| Short return visit (20+ min) | 30 | $2,099 | $62 |
| New patient visit (30+ min) | 22 | $1,854 | $84 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,353 | $104 |
| Measurement of liver stiffness | 17 | $529 | $31 |
2022: 9 services
| Return visit (30+ min) | 68 | $7,923 | $110 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 29 | $6,514 | $225 |
| New patient visit (45+ min) | 24 | $3,506 | $146 |
| Short return visit (20+ min) | 34 | $2,648 | $78 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,600 | $173 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 27 | $2,425 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,334 | $90 |
| New patient visit (30+ min) | 23 | $2,171 | $94 |
| Biopsy of large bowel using a flexible endoscope | 14 | $1,015 | $73 |
2019: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $5,817 | $63 |
| Hospital discharge day management, more than 30 minutes | 39 | $4,104 | $98 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 34 | $3,657 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $3,574 | $85 |
| Initial hospital observation care per day, typically 50 minutes | 11 | $1,457 | $121 |
2018: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $9,450 | $92 |
| Hospital discharge day management, more than 30 minutes | 84 | $8,418 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 49 | $6,104 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,994 | $120 |
| Initial hospital observation care per day, typically 50 minutes | 16 | $1,914 | $120 |
Medicaid work
$597 in 2019
Medicaid paid $597 for 41 billed services this clinician did in 2019, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 28 | $378 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 13 | $219 |
| 2019 | 41 | 2 | 14 | $597 |
Drugs they prescribed that Part D paid
$194,435
Pharmacies billed $194,435 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 553) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
398 generic and 155 brand-name prescriptions · $194,435 in drug cost · 29 antibiotic prescriptions to 16 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 59 | $65,393 | $1,108 |
| Creon | 24 | $55,795 | $2,325 |
| Sod Sulf-Potass Sulf-Mag Sulf | 94 | $5,997 | $64 |
| Omeprazole | 89 | $1,229 | $14 |
| Esomeprazole Magnesium | 23 | $1,072 | $47 |
See all 10 drugs
| Linzess | 59 | $65,393 | $1,108 |
| Creon | 24 | $55,795 | $2,325 |
| Sod Sulf-Potass Sulf-Mag Sulf | 94 | $5,997 | $64 |
| Omeprazole | 89 | $1,229 | $14 |
| Esomeprazole Magnesium | 23 | $1,072 | $47 |
| Pantoprazole | 56 | $1,049 | $19 |
| Dicyclomine | 14 | $933 | $67 |
| Famotidine | 29 | $623 | $21 |
| Peg 3350-Electrolyte | 16 | $372 | $23 |
| Metronidazole | 11 | $57 | $5 |
Year by year
| 2024 | 553 | 229 | 0% (0) | 28% | $194,435 |
| 2023 | 530 | 271 | None | 24% | $132,286 |
| 2022 | 357 | 153 | None | None | $187,997 |
| 2021 | 224 | 65 | 0% (0) | 17% | $30,442 |
| 2020 | 116 | 42 | 0% (0) | 16% | $48,283 |
| 2019 | 192 | 80 | None | None | $56,289 |
| 2018 | 135 | 62 | None | 15% | $5,053 |
| 2017 | 249 | 32 | None | 13% | $16,083 |
| 2016 | 404 | 48 | None | 20% | $25,126 |
| 2015 | 275 | 55 | None | None | $27,981 |
| 2014 | 23 | None | None | None | $1,196 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Linzess | 26 | $26,530 | $1,020 |
| Sod Sulf-Potass Sulf-Mag Sulf | 123 | $9,486 | $77 |
| Esomeprazole Magnesium | 18 | $3,113 | $173 |
| Omeprazole | 127 | $2,614 | $21 |
| Famotidine | 42 | $835 | $20 |
| Pantoprazole | 46 | $604 | $13 |
| Dicyclomine | 14 | $422 | $30 |
2022: 7 drugs
| Linzess | 15 | $12,739 | $849 |
| Sod Sulf-Potass Sulf-Mag Sulf | 21 | $1,645 | $78 |
| Suprep | 14 | $1,525 | $109 |
| Omeprazole | 93 | $1,375 | $15 |
| Pantoprazole | 47 | $779 | $17 |
| Famotidine | 22 | $340 | $15 |
| Metronidazole | 11 | $138 | $13 |
2021: 6 drugs
| Linzess | 19 | $12,354 | $650 |
| Omeprazole | 45 | $669 | $15 |
| Pantoprazole | 53 | $509 | $10 |
| Dicyclomine | 15 | $420 | $28 |
| Peg-3350 and Electrolytes | 14 | $162 | $12 |
| Sertraline | 13 | $27 | $2 |
2020: 4 drugs
| Mesalamine | 11 | $13,547 | $1,232 |
| Pantoprazole | 21 | $297 | $14 |
| Gavilyte-G | 12 | $143 | $12 |
| Omeprazole | 12 | $88 | $7 |
2019: 2 drugs
| Mesalamine | 12 | $15,330 | $1,277 |
| Levofloxacin | 13 | $169 | $13 |
2017: 6 drugs
| Metoprolol | 11 | $271 | $25 |
| Metformin | 31 | $177 | $6 |
| Atorvastatin | 16 | $152 | $9 |
| Lisinopril | 26 | $136 | $5 |
| Atenolol | 11 | $82 | $7 |
| Hydrochlorothiazide | 15 | $81 | $5 |
2016: 8 drugs
| Proair Hfa | 12 | $651 | $54 |
| Pravastatin | 29 | $254 | $9 |
| Atorvastatin | 15 | $129 | $9 |
| Metformin | 28 | $124 | $4 |
| Amlodipine Besylate | 25 | $94 | $4 |
| Lisinopril | 27 | $83 | $3 |
| Hydrochlorothiazide | 12 | $70 | $6 |
| Carvedilol | 11 | $39 | $4 |
2015: 5 drugs
| Clopidogrel | 12 | $207 | $17 |
| Carvedilol | 12 | $71 | $6 |
| Lisinopril | 13 | $70 | $5 |
| Amlodipine Besylate | 13 | $67 | $5 |
| Furosemide | 14 | $43 | $3 |
Money from drug and device companies
$411 in 2025
| 2025 | 6 | 15 | None | $411 |
| 2024 | 3 | 8 | None | $284 |
| 2023 | 8 | 36 | None | $806 |
| 2022 | 4 | 6 | None | $232 |
| 2021 | 4 | 6 | None | $348 |
| 2019 | 1 | 2 | None | $87 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Skyrizi | $276 | 9 payments
|
| Pfizer | Xeljanz | $53 | 2 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $35 | 1 payment
|
| Legend Biotech USA | Carvykti | $19 | 1 payment
|
| Celltrion USA | Vegzelma | $14 | 1 payment
|
| Conmed | Conmed Biliary | $14 | 1 payment
|
See all 15 published payments
| Celltrion USA | Meals · 2025-12-18 | Vegzelma | $14 |
| Abbvie | Meals · 2025-12-17 | Rinvoq | $24 |
| Abbvie | Meals · 2025-12-01 | Creon | $29 |
| Abbvie | Meals · 2025-10-20 | Creon | $7 |
| Abbvie | Meals · 2025-10-17 | Rinvoq | $8 |
| Pfizer | Meals · 2025-10-15 | Velsipity | $21 |
| Conmed | Meals · 2025-10-04 | Conmed Biliary | $14 |
| Abbvie | Meals · 2025-09-25 | Skyrizi | $122 |
| Abbvie | Meals · 2025-09-04 | Creon | $30 |
| Abbvie | Meals · 2025-08-13 | Skyrizi | $24 |
| Pfizer | Meals · 2025-08-06 | Xeljanz | $32 |
| Abbvie | Meals · 2025-07-28 | Creon | $8 |
| Legend Biotech USA | Meals · 2025-05-16 | Carvykti | $19 |
| Abbvie | Meals · 2025-04-25 | Creon | $25 |
| Madrigal Pharmaceuticals | Meals · 2025-04-25 | Rezdiffra | $35 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $284
| Abbvie | Skyrizi | $235 | 6 payments
|
| Janssen Biotech | Tremfya | $29 | 1 payment
|
| Pfizer | Xeljanz | $20 | 1 payment
|
2023: $806
| AbbVie | Rinvoq | $429 | 17 payments
|
| QOL Medical | Sucraid | $107 | 6 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $94 | 5 payments
|
| Nestle Healthcare Nutrition | Zenpep | $63 | 3 payments
|
| Merck Sharp & Dohme | Dificid | $49 | 2 payments
|
| Pfizer | Xeljanz | $25 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $22 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $16 | 1 payment
|
2022: $232
| E.R. Squibb & Sons L.L.C. | Zeposia | $120 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $46 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $45 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $21 | 1 payment
|
2021: $348
| E.R. Squibb & Sons L.L.C. | Zeposia | $122 | 1 payment
|
| Gilead Sciences | Epclusa | $113 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $96 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $18 | 1 payment
|
2019: $87
| Gilead Sciences | Epclusa | $87 | 2 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 91.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1417367467
- Licence
- CA A148786California A148786: Current · expires 2026-11-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2014-04-29
- NPI last updated
- 2023-09-05
- NPI record certified
- 2023-09-05
This is when the NPI record was last certified, not a medical board exam.